Ibrutinib plus CIT for RR mature BNHL in children SPARKLE trial initial safety pharmacokinetics and efficacy

Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy

12:19 EST 19 Feb 2020 | Nature Publishing

More From BioPortfolio on "Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy"